Treatment of Opioid Induced Constipation
Opioids are the most commonly prescribed medication for the treatment of severe pain. However, opioid use can produced multiple adverse side-effects which include drug abuse, dependence, and constipation. These side-effects are mostly attributed to opioid binding at mu opioid receptors in the central nervous system.
Researchers at Virginia Commonwealth University have developed a nanoparticle-based opioid conjugate that has increased bioavailability and carrying capacity of a peripheral nervous system selective opioid antagonist. This conjugate has excellent oral availability and half-life with the potential to treat opioid induced constipation. Nanoparticle-based delivery systems provide additional stability to the opioid ligand, and produces very low therapeutic side effects.
Chart showing P(EAMO)-NAP-PEG effects on intestinal motility in acute morphine treated mice through oral administration [View Image]
Figure 1. P(EAMO)-NAP-PEG effects on intestinal motility in acute morphine treated mice through oral administration.
- Treat constipation without compromising pain relief of opioids
- No opioid abuse liability
- No opioid dependence
- Does not affect the CNS
- Low dose requirement with slow release potential
- Opioid induced constipation
In vitro and in vivo data available
Patent issued: U.S. rights are available. 15/998,948
This technology is available for licensing to industry for further development and commercialization.
VCU Tech #:
Contact us about
Magdalena K. Morgan, Ph.D.